Across TCGA pan-cancer cohorts, LINC01857 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated LINC01857 data layer.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LINC01857 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated LINC01857 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.
LUAD, HNSC, and CESC are the cancer types where LINC01857 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.